

06-27-05

1626  
252

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:	10/500,999	Art Unit:	1626
Filed:	10/01/2004	Examiner:	tba
1 <sup>st</sup> Inventor:	Jun-ichi Kawakami	Allowed:	
For:	Process for Producing Fused Imidazole Compound, Reformatsky Reagent in Stable Form, and Process for Producing the Same	Batch:	
Atty. Dkt. No.	3010 USOP	Paper No.:	

**CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10**

**USPS EXPRESS MAIL LABEL. No. EV 524904865 US**

**DATE IN: June 24, 2005**

**Itemized Papers/Items:**


1. This Certificate of Express Mailing and Return Postcard (2 pages)
2. Transmittal Form (1 page X 2)
3. Supplemental Information Disclosure Statement (1 page) with Form PTO/SB/08B (1 page), and cited reference (1)
4. Supplementary Partial European Search Report (3 pages)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:


MAIL STOP AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on this date, June 24, 2005

Dated: 6/24/05

  
Gail L. Winokur

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
475 Half Day Road  
Lincolnshire, IL 60069 USA



PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

9

Application Number

10/500,999

Filing Date

10/01/2004

First Named Inventor

Jun-ichi Kawakami

Art Unit

1626

Examiner Name

tba

Attorney Docket Number

3010 USOP

**ENCLOSURES (Check all that apply)**

Fee Transmittal Form



Fee Attached



Amendment/Reply



After Final



Affidavits/declaration(s)



Extension of Time Request



Express Abandonment Request



Information Disclosure Statement



Certified Copy of Priority Document(s)

Reply to Missing Parts/  
Incomplete ApplicationReply to Missing Parts  
under 37 CFR 1.52 or 1.53

Drawing(s)



Licensing-related Papers



Petition



Petition to Convert to a



Provisional Application



Power of Attorney, Revocation



Change of Correspondence Address



Terminal Disclaimer



Request for Refund



CD, Number of CD(s) \_\_\_\_\_

☐ Landscape Table on CD

After Allowance Communication to TC

Appeal Communication to Board  
of Appeals and InterferencesAppeal Communication to TC  
(Appeal Notice, Brief, Reply Brief)

Proprietary Information



Status Letter

Other Enclosure(s) (please identify  
below):

Return Postcard;

Certificate of Express Mailing;

Cited Reference (1)

Supplementary Partial European Search  
Report**Remarks**The Commissioner is hereby authorized to charge any additional fees which may be required,  
or credit any overpayment to Deposit Account 500799.**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name

Signature

Printed name

Mark Chao, Ph.D., JD

Date

Reg. No.

37,293

**CERTIFICATE OF TRANSMISSION/MAILING**I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with  
sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on  
the date shown below:

Signature

Typed or printed name

Gail L. Winokur

Date

6/24/05

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Express mail to: EVS24904865 US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:	10/500,999	Art Unit:	1626
Filed:	10/01/2004	Examiner:	tba
1 <sup>st</sup> Inventor:	Jun-ichi Kawakami	Allowed:	
For:	Process for Producing Fused Imidazole Compound, Reformatsky Reagent in Stable Form, and Process for Producing the Same	Batch:	
Atty. Dkt. No.	3010 USOP	Paper No.:	

**Supplemental Information Disclosure Statement**

MAIL STOP AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, applicants request consideration of the reference listed on the attached Form PTO/SB/08B. A legible copy of each listed reference is herewith being provided to the Examiner.

This reference was cited in Communication dated April 6, 2005, issued in the foreign application corresponding to the above-identified application. No fee is required for this filing.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call applicants' attorney at (847) 383-3372.

Respectfully submitted,


Dated:

6/23/05

(847) 383-3372  
(847) 383-3391

Mark Chao, Ph.D., Reg. No. 37,293  
Elaine M. Ramesh, Ph.D., Reg. No. 43,032  
Attorney for Applicants  
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
475 Half Day Road  
Lincolnshire, IL 60069 USA



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/116

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number 10/500,999

Filing Date 10/01/2004

First Named Inventor J. Kawakami

Art Unit 1626

Examiner Name tba

Attorney Docket Number 3010 USOP

Sheet 1 of 1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	B1	J.J. CHEN, et al., "Synthesis and Activity of Conformationally-Constrained Macrocyclic Norstatine-Based Inhibitors of HIV Protease", Biorganic & Medicinal Chemistry Letters, (1996), pp. 435-438, Vol. 6, No. 4.	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.